Literature DB >> 26365474

Impact of platelet rich plasma and adipose stem cells on lymphangiogenesis in a murine tail lymphedema model.

Maximilian Ackermann1, Reto Wettstein2, Christopher Senaldi3, Daniel F Kalbermatten2, Moritz A Konerding1, Wassim Raffoul3, Paolo Erba4.   

Abstract

BACKGROUND: Lymphedema is an underdiagnosed pathology which in industrialized countries mainly affects cancer patients that underwent lymph node dissection and/or radiation. Currently no effective therapy is available so that patients' life quality is compromised by swellings of the concerned body region. This unfortunate condition is associated with body imbalance and subsequent osteochondral deformations and impaired function as well as with an increased risk of potentially life threatening soft tissue infections.
METHODS: The effects of PRP and ASC on angiogenesis (anti-CD31 staining), microcirculation (Laser Doppler Imaging), lymphangiogenesis (anti-LYVE1 staining), microvascular architecture (corrosion casting) and wound healing (digital planimetry) are studied in a murine tail lymphedema model.
RESULTS: Wounds treated by PRP and ASC healed faster and showed a significantly increased epithelialization mainly from the proximal wound margin. The application of PRP induced a significantly increased lymphangiogenesis while the application of ASC did not induce any significant change in this regard.
CONCLUSIONS: PRP and ASC affect lymphangiogenesis and lymphedema development and might represent a promising approach to improve regeneration of lymphatic vessels, restore disrupted lymphatic circulation and treat or prevent lymphedema alone or in combination with currently available lymphedema therapies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adipose stem cells; Angiogenesis; Corrosion casting; Lymphatic regeneration; Lymphoedema; PRP

Mesh:

Year:  2015        PMID: 26365474     DOI: 10.1016/j.mvr.2015.09.001

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  7 in total

1.  Hemostasis stimulates lymphangiogenesis through release and activation of VEGFC.

Authors:  Lillian Lim; Hung Bui; Olivia Farrelly; Jisheng Yang; Li Li; David Enis; Wanshu Ma; Mei Chen; Guillermo Oliver; John D Welsh; Mark L Kahn
Journal:  Blood       Date:  2019-11-14       Impact factor: 22.113

2.  Impact of Platelet-Rich Plasma on Viability and Proliferation in Wound Healing Processes after External Radiation.

Authors:  Yvonne Reinders; Oliver Felthaus; Gero Brockhoff; Fabian Pohl; Norbert Ahrens; Lukas Prantl; Frank Haubner
Journal:  Int J Mol Sci       Date:  2017-08-22       Impact factor: 5.923

Review 3.  Use of Autologous Blood Components in Lymphedema Treatment: A Systematic Review.

Authors:  Antonio J Forte; Daniel Boczar; Maria T Huayllani; Sanjay Bagaria; Sarah A McLaughlin
Journal:  Cureus       Date:  2019-09-12

Review 4.  Therapeutic Potential of Mesenchymal Stem Cells for Postmastectomy Lymphedema: A Literature Review.

Authors:  Kuo Chen; Mikhail Y Sinelnikov; Igor V Reshetov; Petr Timashev; Yuanting Gu; Lan Mu; Pengwei Lu; Yuanyuan Zhang
Journal:  Clin Transl Sci       Date:  2020-08-30       Impact factor: 4.689

Review 5.  Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis.

Authors:  Hector Lafuente; Ibon Jaunarena; Eukene Ansuategui; Arantza Lekuona; Ander Izeta
Journal:  Stem Cell Res Ther       Date:  2021-11-20       Impact factor: 6.832

6.  Adipose tissue-derived microvascular fragments promote lymphangiogenesis in a murine lymphedema model.

Authors:  Florian S Frueh; Laura Gassert; Claudia Scheuer; Andreas Müller; Peter Fries; Anne S Boewe; Emmanuel Ampofo; Claudia E Rübe; Michael D Menger; Matthias W Laschke
Journal:  J Tissue Eng       Date:  2022-07-26       Impact factor: 7.940

Review 7.  Emerging Anti-Inflammatory Pharmacotherapy and Cell-Based Therapy for Lymphedema.

Authors:  Ryohei Ogino; Tomoharu Yokooji; Maiko Hayashida; Shota Suda; Sho Yamakawa; Kenji Hayashida
Journal:  Int J Mol Sci       Date:  2022-07-09       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.